Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-10-16
2007-10-16
Yaen, Christopher H. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007500, C435S007900, C435S007920, C436S064000, C436S813000
Reexamination Certificate
active
08158939
ABSTRACT:
Disclosed are methods and compositions for identifying malignant tumors that overexpress the c-erbB-2 oncogene. Assays useful for diagnosis and prognosis of neoplastic disease are provided which detect the external domain of c-erbB-2, the glycoprotein gp75 and quantitate the level of gp75 in the biological fluids of mammals carrying a tumor burden.Further disclosed are recombinant, synthetically and otherwise biologically produced novel proteins and polypeptides which are encoded by the external domain DNA sequence of the c-erbB-2 oncogene (the gp75 gene) or fragments thereof. Such gp75 proteins and polypeptides are useful as vaccines, therapeutically in the treatment of cancer either alone or in combination with chemotherapeutic agents.Also disclosed are antibodies to such gp75 proteins and polypeptides which are useful diagnostically and therapeutically. Still further disclosed are test kits embodying the assays of this invention.
REFERENCES:
patent: 4699877 (1987-10-01), Cline et al.
patent: 4753894 (1988-06-01), Frankel et al.
patent: 4933294 (1990-06-01), Waterfield et al.
patent: 4935341 (1990-06-01), Bargmann et al.
patent: 4968603 (1990-11-01), Slamon et al.
patent: 5401638 (1995-03-01), Carney et al.
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5720954 (1998-02-01), Hudziak et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5772997 (1998-06-01), Hudziak et al.
patent: 6015567 (2000-01-01), Hudziak et al.
patent: 6836414 (2004-12-01), Aaronson et al.
patent: 8707646 (1987-12-01), None
patent: 8901973 (1989-03-01), None
patent: 8906692 (1989-07-01), None
patent: 8910412 (1989-11-01), None
patent: 9105264 (1991-04-01), None
Carney, WP, et al.,Journal of Tumor Marker Oncology, vol. 6, N o. 2, pp. 53-72, 1991.
Masuko, T, et al.,Jpn. J. Cncer Res., vol. 80, pp. 10-14, Jan. 1989.
Drebin, JA, et al.,Oncogene, vol. 2, pp. 273-277, 1988.
McKenzie, SJ, et al,Oncogene, vol. 4, No. 5, pp. 543-548, May 1989.
Chan and McGee, “Cellular oncogenes in neoplasia,”J. Clin. Pathol.40: 1055-1063 (1987).
Cline and Battifora, “Abnormalities of Protooncogenes in Non-Small Cell Lung Cancer,”Cancer, 60: 2669-2674 (1987).
Schneider et al., “Differential Expression of the c-erbB-2 Gene in Human Cell and Non-Small Cell Lung Cancer,”Cancer Research, 49: 4968-4971 (Sep. 15, 1989).
Akiyma et al., “Antibodies to a peptide produced by cancer-related C=erbB-2 gene,”Chemical Abstracts, 107:570 (Abstract # 172403m) (1987).
Bargmann et al., “Theneuoncogene encodes an epidermal growth factor receptor-related protein”,Nature, 319:226-230 (1986).
Berger et al., “Correlation of c-erbB-2 Gene Amplification and Protein Expression in Human Breast Carcinoma With Nodal Status and Nuclear Grading,”Cancer Research, 48: 1238-1243 (Mar. 1, 1988).
Bernards et al., “Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector”,PNAS(USA) 84: 6854-6858 (1987).
Brandt-Rauf et al., “Detection of Increased Amounts of the Extracellular Domain of the c-erbB-2 Oncoprotein in Serum During Pulmonary Carcinogenesis in Humans,”Int. J. Cnacer, 56: 383-386 (1994).
Breuer et al., “Detection of elevated c-erbB-2 oncoprotein in the serum and tissue in breast cancer,”Med. Sci. Res., 21: 383-384 (1993;.
Chiba et al., “Growth-associated Shedding of a Tumor Antigen (CE7) Detected by a Monoclonal Antibody”,Cancer Research, 49: 3972-3975 (Jul. 18, 1989).
Coussens et al., “Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location withneuOncogene”,Science, 230: 1132-1139 (Dec. 6, 1985).
Di Fiore et al., “erbB-2 is a Potent Oncogene When Overexpressed in NIH/3T3 Cells”,Science, 237: 178-182 (1987).
Drebin et al., “Down-Modulation of an Oncogene Protein Product and Reversion of the Transformed Phenotype by Monoclonal Antibodies”,Cell, 41: 695-706 (1985).
Drebin et al., “Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen,”PNAS(USA) 83: 9129-9133 (Dec. 1986).
Gullick et al., “Expression of the c-erbB-2 Protein in Normal and Transformed Cells,”Int. J. Cancer, 40:246-254 (1987).
Hudziak et al., “p185HER2Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor”,Mol. Cell. Biol., 9(3): 1165-1172 (1989).
Hung et al., “Molecular cloning of theneugene: Absence of gross structural alteration in oncogenic alleles”,PNAS(USA), 83: 261-264 (1986).
Iacobelli et al., “Detection of Antigens Recognized by a Novel Monoclonal Antibody in Tissue and Serum from Patients with Breast Cancer”,Cancer Research, 46:3005-3010 (1986).
Isola et al., “ElevatederbB-2 Oncoprotein Levels in Preoperative and Follow-up Serum Samples Define an Aggressive Disease Course in Patients with Breast Cancer,”Cancer, 73(3):653-658 (Feb. 1, 1994).
King et al., “Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma”,Science, 229: 972-974 (Dec. 1985).
Langton et al., “The development and characterization of antibodies to different regions of the c-erbB -2 protein on breast tumor tissue and cell lines” (Abstract and Poster), presented at the 1989 American Association for Cancer Research Conference (May 24-27, 1989).
Loughnan et al., “Soluble interleukin 2 receptors are released from the cell surface of normal murine B lymphocytes stimulated with interleukin 5,”PNAS(USA), 85: 3115-3119 (19880.
Maguire and Greene, “Theneu(c-erbB-2) Oncogene,”Seminars in Oncology, 16 (2): 148-155 (Apr. 1989).
McCann et al., “c-erbB-2 Oncoprotein Expression in Malignant and Nonmalignant Breast Tissue,”I.J.M.S., 158 (6): 137-140 (Jun. 1989).
Merlino, et al., “Amplification and Enhanced Expression of the Epiderman Growth Factor Receptor Gene in A431 Human Carcinoma Cells,”Science, 224: 417-419 (1984).
Myones et al., “Identification of a Spontaneously Shed Fragment of B Cell Complement Receptor Type Two (CR2) Containing the C3d-Binding Site”,Complement, 4: 87-98 (1987).
Price et al., “The Production and Characterisation of Monoclonal Antibodies to myc, c-erb-B-2 and EGF-receptor Using a Synthetic Peptide Approach”, [Symposium on Monoclonal Antibodies for Therapy, Prevention and in vitro Diagnosis of Human Disease, (Ulrecht, The Netherlands; May 17-19, 1989)]Develop. Biol. Standarad, 71: 23-31 (1990).
Ring et al., “Distribution and Physical Properties of BCA200, a M 200,000 Glycoprotein Selectively Associated with Human Breast Cancer”,Cancer Research, 49: 3070-3080 (1989).
Sainsbury et al., “Epidermal-Growth-Factor Receptor Status as Predictor of Early Recurrence of and Death from Breast Cancer”,The Lancet:1398-1402 (Jun. 20, 1987).
Schechter, et al., TheneuGene: An erbB-Homologous Gene Distinct from and Unlinked to the Gene Encoding the EGF Receptor,Science, 229: 976-978 (1985).
Setton et al., “neusabout c-erb-B-2 and HER2”,TIG, 4: 247-248 (1988).
Semba et al., “A v-erbB-related protoonocogene, c-erbB-2, is distinct from the c-erB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma”,PNAS(USA), 82: 6497-6501 (1985).
Slamon et al., “Human Breast Cancer: Correlation or Relapse and Survival with Amplification of HER-2
eu Oncogene”,Science, 235: 177-182 (1987).
Slamon et al., “Studies of the HER-2
eu Proto-oncogene in Human Breast and Ovarian Cancer”,Science, 244: 707-712 (1989).
Tuzi et al., “Production and characterization of monoclonal antibodies to the c-erbB-2 proto-oncogene protein using a synthetic pepetide immunogen”,Biochemical Society Transactions65th Meeting, London (1988).
Ullrich et al., “Human Epidermal Growth Factor Re
Hancock Miriam E. C.
Langton Beatrice Claudia
Monahan John J.
Harland Joan C.
Lauder Leona L.
Schering AG
Yaen Christopher H.
LandOfFree
C-erbB-2 external domain: GP75 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with C-erbB-2 external domain: GP75, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C-erbB-2 external domain: GP75 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3828451